Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with … E Tartour, H Pere, B Maillere, M Terme, N Merillon, J Taieb, F Sandoval, ... Cancer and Metastasis Reviews 30, 83-95, 2011 | 361 | 2011 |
Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy M Worm, HH Lee, J Kleine-Tebbe, RP Hafner, P Laidler, D Healey, ... Journal of Allergy and Clinical Immunology 127 (1), 89-97. e14, 2011 | 210 | 2011 |
Induction of interleukin‐10 and suppressor of cytokine signalling‐3 gene expression following peptide immunotherapy M Tarzi, S Klunker, C Texier, A Verhoef, SO Stapel, CA Akdis, B Maillere, ... Clinical & Experimental Allergy 36 (4), 465-474, 2006 | 179 | 2006 |
HLA-DR restricted peptide candidates for bee venom immunotherapy C Texier, S Pouvelle, M Busson, M Hervé, D Charron, A Ménez, ... The Journal of Immunology 164 (6), 3177-3184, 2000 | 163 | 2000 |
NY-ESO-1 119–143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1-and Th2-type tumor-reactive CD4+ T cells HM Zarour, B Maillere, V Brusic, K Coval, E Williams, S Pouvelle-Moratille, ... Cancer research 62 (1), 213-218, 2002 | 155 | 2002 |
Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules R Chiari, G Hames, V Stroobant, C Texier, B Maillère, T Boon, PG Coulie Cancer research 60 (17), 4855-4863, 2000 | 147 | 2000 |
HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity FA Castelli, C Buhot, A Sanson, H Zarour, S Pouvelle-Moratille, C Nonn, ... The Journal of Immunology 169 (12), 6928-6934, 2002 | 141 | 2002 |
Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy … Y Godet, E Fabre, M Dosset, M Lamuraglia, E Levionnois, P Ravel, ... Clinical Cancer Research 18 (10), 2943-2953, 2012 | 132 | 2012 |
Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers L Van Overtvelt, E Wambre, B Maillere, E von Hofe, A Louise, AM Balazuc, ... The Journal of Immunology 180 (7), 4514-4522, 2008 | 129 | 2008 |
CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A M Jacquemin, V Vantomme, C Buhot, R Lavend'homme, W Burny, ... Blood, The Journal of the American Society of Hematology 101 (4), 1351-1358, 2003 | 128 | 2003 |
Frequency of epitope-specific naive CD4+ T cells correlates with immunodominance in the human memory repertoire WW Kwok, V Tan, L Gillette, CT Littell, MA Soltis, RB LaFond, J Yang, ... The Journal of Immunology 188 (6), 2537-2544, 2012 | 126 | 2012 |
Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy L Zuidmeer-Jongejan, H Huber, I Swoboda, N Rigby, SA Versteeg, ... International archives of allergy and immunology 166 (1), 41-51, 2015 | 106 | 2015 |
Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analog F Monneaux, J Hoebeke, C Sordet, C Nonn, JP Briand, B Maillere, ... The Journal of Immunology 175 (9), 5839-5847, 2005 | 97 | 2005 |
Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPARγ/STAT5 signaling pathway in macaques S Prost, M Le Dantec, S Augé, R Le Grand, S Derdouch, G Auregan, ... The Journal of clinical investigation 118 (5), 1765-1775, 2008 | 88 | 2008 |
FAST: towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies L Zuidmeer-Jongejan, M Fernandez-Rivas, LK Poulsen, A Neubauer, ... Clinical and translational allergy 2, 1-9, 2012 | 85 | 2012 |
Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve C Oseroff, B Peters, V Pasquetto, M Moutaftsi, J Sidney, V Panchanathan, ... The Journal of Immunology 180 (11), 7193-7202, 2008 | 84 | 2008 |
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines … Clinical & Experimental Immunology 181 (3), 385-400, 2015 | 82 | 2015 |
Complementarity and redundancy of the binding specificity of HLA‐DRB1,‐DRB3,‐DRB4 and‐DRB5 molecules C Texier, S Pouvelle‐Moratille, M Busson, D Charron, A Ménez, ... European journal of immunology 31 (6), 1837-1846, 2001 | 80 | 2001 |
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing … M Mandic, F Castelli, B Janjic, C Almunia, P Andrade, D Gillet, V Brusic, ... The Journal of Immunology 174 (3), 1751-1759, 2005 | 79 | 2005 |
Characterization of CD4 T cell epitopes of infliximab and rituximab identified from healthy donors M Hamze, S Meunier, A Karle, A Gdoura, A Goudet, N Szely, M Pallardy, ... Frontiers in immunology 8, 500, 2017 | 75 | 2017 |